1. Background
2. Objectives
3. Methods
3.1. Preparation of Nanostructured Silymarin
3.2. Characterization of Nanostructured Silymarin
3.2.1. Animals
3.2.2. Experimental Design
3.3. Biochemical Tests
3.4. Histology Changes
3.5. Real-time Polymerase Chain Reaction
3.6. Data Analysis
4. Results
4.1. Characterization of Nanostructured Silymarin
| Nanoparticles | Particle Size (nm) | PDI | ZP | EE (%) |
|---|---|---|---|---|
| SM-PLGA | 82.3 ± 5.8 | 0.14 ± 0.05 | -28.4 | 89.18 ± 6.4 |
| Blank-PLGA | 80.13 ± 6.7 | 0.12 ± 0.06 | -27.3 | - |
Abbreviations: ZP, Zeta potential; PDI, polydispersity index; EE, encapsulation efficacy; SM, silymarin; PLGA, poly(lactic-co-glycolic acid).
a Values are expressed as mean ± standard deviation.
4.2. Organ Weight
4.3. Biochemical Tests
Biochemical tests in various groups (mean ± standard deviation; n = 8) control, silymarin (SM), nanostructured silymarin (NSM), acetaminophen (APAP), SM + APAP, NSM + APAP; * P < 0.05, ** P < 0.01, # P < 0.05, and ## P < 0.01; * and # indicating comparison to the control and acetaminophen groups
4.4. Histology
Expression of BAX and BCL-2 in various groups; control, silymarin (SM), nanostructured silymarin (NSM), acetaminophen (APAP), SM + APAP, NSM + APAP (mean ± standard deviation; n = 5); * P < 0.05, ** P < 0.01, *** P < 0.001, # P < 0.05, ## P < 0.01, and ### P < 0.001; * and # indicating comparison to the control and acetaminophen groups
4.5. Real-time Polymerase Chain Reaction
Micrographs of hematoxylin-eosin-stained slides of various groups; control, silymarin (SM), nanostructured silymarin (NSM), acetaminophen (APAP), SM + APAP, NSM + APAP; I, infiltration of inflammatory cells; C, congestion of red blood cells; P, damaged proximal tubules; magnifications: X100




